CODING & REIMBURSEMENT FOR THE 2024-2025 SEASON

CPT Codes for Flu Vaccines and Flu Vaccine Reimbursement Information

Influenza Vaccine - Fluzone High-Dose Fluzone Influenza Vaccine

FLUZONE HIGH-DOSE
(SINGLE-DOSE PREPARATION)1-3

Presentation
and Doseᵃ
10 single-dose
0.5 mL prefilled
syringes
Vaccine CPTᵇ® Code
90662
When the Payer Requires the
Outer Carton NDCᶜ
49281-124-65
When the Payer Requires the
Unit-of-Use NDC
49281-124-88
CVXᵈ Code
135

90662 - Influenza virus vaccine (HD-IIV3), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use.

FLUBLOK
(SINGLE-DOSE PREPARATION)2-4

Presentation
and Doseᵃ
10 single-dose
0.5-mL prefilled
syringes
Vaccine CPTᵇ Code
90673
When the Payer Requires the
Outer Carton NDCᶜ
49281-724-10
When the Payer Requires the
Unit-of-Use NDC
49281-724-88
CVXᵈ Code
155

90673 - Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use.

FLUZONE
(SINGLE-DOSE PREPARATION)2,3,5

Presentation
and Doseᵃ
10 single-dose 0.5-mL prefilled syringes
Vaccine CPTᵇ Code
90656
When the Payer Requires the
Outer Carton NDCᶜ
49281-424-50
When the Payer Requires the
Unit-of-Use NDC
49281-424-88
CVXᵈ Code
140

90656 - Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5-mL dosage, for intramuscular use.

FLUZONE
(MULTI-DOSE PREPARATION)2,3,5

Presentation
and Doseᵃ
0.25-mL dose taken from 5-mL multi-dose vial0.5-mL dose taken from 5-mL multi-dose vial
Vaccine CPTᵇ Code
90657 (0.25-mL dose)90658 (0.5-mL dose)
When the Payer Requires the
Outer Carton NDCᶜ
49281-641-15
When the Payer Requires the
Unit-of-Use NDC
49281-641-78
CVXᵈ Code
141

90657 - Influenza virus vaccine, trivalent (IIV3), split virus, 0.25-mL dosage, for intramuscular use.

90658 - Influenza virus vaccine, trivalent (IIV3), split virus, 0.5-mL dosage, for intramuscular use.

Source: 2024 CPT.
aA maximum of 10 doses can be withdrawn from the multi-dose vial.
bCPT (Current Procedural Terminology) is a registered trademark of the American Medical Association.
cNDC=National Drug Code.
dCode that indicates products used in vaccination.
Notice: This coding information is provided for informational purposes only and does not constitute legal or reimbursement advice. It is not intended to substitute for the physician’s independent
diagnosis or treatment of each patient. The information contained herein is gathered from various resources and is subject to change. Providers are solely responsible for the accuracy of all coding and
claims submitted for reimbursement to any third-party payer.

You are about to leave SanofiFlu.com

Would you like to continue?

CLOSE WINDOW

INDICATIONS

Fluzone, Flublok, and Fluzone High-Dose are vaccines indicated for active immunization for the prevention of disease caused by influenza A virus subtypes and type B virus contained in (or in the case of Flublok, represented by antigens contained in) the vaccine. Fluzone is approved for use in persons 6 months of age and older. Flublok is approved for use in persons 18 years of age and older. Fluzone High-Dose is approved for use in persons 65 years of age and older.

IMPORTANT SAFETY INFORMATION

arrow down

Do not administer Fluzone, Flublok, or Fluzone High-Dose to anyone with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine (including egg protein for Fluzone and Fluzone High-Dose). Fluzone and Fluzone High-Dose should not be administered to anyone who has had a severe allergic reaction after previous dose of any influenza vaccine.

Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of the vaccine.

If Guillain-Barré syndrome has occurred within 6 weeks following previous influenza vaccination, the decision to give Fluzone, Flublok, or Fluzone High-Dose should be based on careful consideration of the potential benefits and risks.

If Fluzone, Flublok, or Fluzone High-Dose are administered to immunocompromised persons, including those receiving immunosuppressive therapy, the expected immune response may not be attained.

Vaccination with Fluzone, Flublok, or Fluzone High-Dose may not protect all recipients.

Syncope (fainting) has been reported following vaccination with Fluzone, Flublok and Fluzone High-Dose. Procedures should be in place to avoid injury from fainting.

For Fluzone, in children 6 months through 8 years of age, the most common injection-site adverse reactions were pain or tenderness and redness; the most common solicited systemic adverse reactions were irritability, drowsiness (6 months through 35 months), and myalgia (3 years through 8 years). In adults 18 through 64 years of age, the most common injection-site adverse reaction was pain; the most common solicited systemic adverse reactions were headache and myalgia. In adults over 65 years of age, the most common injection-site adverse reaction was pain; the most common solicited systemic adverse reactions were headache, myalgia, and malaise.

For Flublok, in adults 18 through 64 years of age, the most common injection site adverse reaction was pain; the most common solicited systemic adverse reactions were headache, fatigue, and myalgia. In adults 65 years of age and older, the most common injection-site adverse reaction was pain; the most common solicited systemic adverse reactions were fatigue and headache.

For Fluzone High-Dose, in adults 65 years of age and older, the most common injection-site reaction was pain; the most common solicited systemic adverse reactions were myalgia, malaise, and headache.

For Fluzone, Flublok, and Fluzone High-Dose, other adverse reactions may occur.

Before administration, please see the full Prescribing Information for Fluzone, Flublok, or Fluzone High-Dose. Also, please see complete Patient Information for Fluzone or Fluzone High-Dose.

Click here to learn more about Sanofi’s commitment to fighting counterfeit drugs.

brands